Soliris Successfully Treats aHUS in COVID-19 Patient With Heart Transplant

Soliris Successfully Treats aHUS in COVID-19 Patient With Heart Transplant

306028

Soliris Successfully Treats aHUS in COVID-19 Patient With Heart Transplant

Soliris (eculizumab) was shown to effectively treat atypical hemolytic uremic syndrome (aHUS) triggered by COVID-19 in a patient who had undergone a heart transplant five years earlier, according to a recent case report study. “We present a case of [a] 32-year-old Hispanic male with a history of heart transplant, admitted with COVID-19 and atypical hemolytic uremic syndrome, which was successfully treated with Eculizumab,” marketed as Soliris, the researchers wrote. The study, “COVID‐19‐associated atypical hemolytic uremic…

You must be logged in to read/download the full post.